| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HMMR; IHABP; RHAMM; Hyaluronan mediated motility receptor; Intracellular hyaluronic acid-binding protein; Receptor for hyaluronan-mediated motility; CD antigen CD168 |
| Entrez GeneID | 3161 |
| WB Predicted band size | Calculated MW: 84 kDa; Observed MW: 84 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human CD168 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于CD168(RHAMM)抗体的参考文献及其摘要概括：
1. **文献名称**: *CD168 expression in breast cancer: a prognostic marker correlated with tumor microenvironment immune response*
**作者**: Smith A, et al.
**摘要**: 研究通过免疫组化分析乳腺癌组织中CD168的表达，发现其高表达与肿瘤相关巨噬细胞浸润及患者不良预后相关，提示CD168可能通过调节肿瘤微环境促进转移。
2. **文献名称**: *Targeting RHAMM/CD168 in glioblastoma: antibody-mediated inhibition of tumor cell migration*
**作者**: Johnson R, et al.
**摘要**: 开发了靶向CD168的单克隆抗体，体外实验显示其可显著抑制胶质母细胞瘤细胞的迁移和侵袭能力，表明CD168抗体在抑制肿瘤浸润中的潜在治疗价值。
3. **文献名称**: *CD168 as a novel biomarker for leukemia stem cell detection*
**作者**: Wang Y, et al.
**摘要**: 利用CD168抗体在急性髓系白血病患者中鉴定出高表达CD168的白血病干细胞亚群，其与化疗耐药性相关，提示CD168可作为白血病干细胞分离及靶向治疗的标志物。
注：以上文献信息为基于领域知识的概括性示例，实际引用需以具体论文数据为准。
CD168 antibody targets the CD168 antigen, also known as Receptor for Hyaluronan-Mediated Motility (RHAMM), encoded by the HMMR gene. RHAMM is a non-integral hyaluronic acid (HA) receptor involved in cell migration, proliferation, and intracellular signaling. Structurally, it lacks a transmembrane domain but interacts with cell surface receptors like CD44 to mediate HA signaling. CD168 is overexpressed in various cancers, including breast, prostate, and leukemia, where it promotes tumor progression, metastasis, and angiogenesis by activating pathways such as MAPK/ERK and PI3K/AKT. Its dysregulation is also linked to inflammatory and autoimmune disorders.
CD168 antibodies are essential tools in research and diagnostics. They enable detection of RHAMM expression via techniques like immunohistochemistry (IHC), flow cytometry, and Western blotting, aiding in cancer prognosis and mechanistic studies. Therapeutic applications are under exploration, with anti-RHAMM antibodies and CAR-T cells being investigated to target cancer cells. However, RHAMM's dual role in physiological processes (e.g., wound healing) and pathological states complicates therapeutic strategies. Current research focuses on understanding its context-dependent functions and optimizing antibody-based interventions. CD168 antibodies thus hold promise for both biomarker discovery and targeted cancer therapies.
×
